Daylight photodynamic therapy for cutaneous leishmaniasis in a pediatric setting: A case report and literature review
Federica Li Pomi1, Lucia Peterle1, Mario Vaccaro1
1Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, Messina 98125, Italy.
Insights
Daylight-photodynamic therapy (DL-PDT) shows promise for treating pediatric cutaneous leishmaniasis (CL), a challenging infection. Further research is needed to standardize DL-PDT protocols for children.
Area of Science:
- Dermatology
- Infectious Diseases
- Pediatrics
Background:
- Cutaneous leishmaniasis (CL) is a parasitic infection affecting children, with limited treatment options due to drug toxicity and resistance.
- Current CL treatments pose risks for pediatric patients, compounded by parental concerns.
Conclusions:
- DL-PDT presents a viable therapeutic option for pediatric CL, particularly in cosmetically sensitive areas.
- Standardization of DL-PDT protocols, including session frequency and intervals, is crucial for pediatric CL treatment through randomized clinical trials.
Abstract:
Cutaneous leishmaniasis (CL) is a vector-borne infection caused by the obligate intracellular parasites of the Leishmania genus. Children are more frequently affected due to increased exposure to sandflies and underdeveloped immune system. Currently, there is a lack of consensus on the most effective treatment approach for CL since most drugs are accompanied by numerous limitations, including adverse effects, toxicity, and onset of antimicrobial resistance phenomena. These limitations appear more relevant in the pediatric population, both for the treatment-related risks and for the reticence of the parents. Photodynamic therapy (PDT) has been increasingly employed in numerous inflammatory and infectious diseases, owing to its tissue selectivity and excellent cosmetic outcomes. On this topic, we report our experience with daylight-PDT (DL-PDT) therapy in a difficult-to-treat area like the facial region in a child with a six-month history of CL. Our case is paradigmatic of the potentiality of PDT to treat difficult lesions in a pediatric setting. However, its use has not yet been standardized either for the treatment of leishmania, with high variability in the number of sessions and time intervals. Specific protocols for pediatric patients should be better standardized in randomized clinical trials in order to provide clear indications for clinicians.
Related Concept Videos
Leishmaniasis
Antiprotozoal Agents


